Summit Therapeutics Inc. 8K

Summit Therapeutics reported that partner Akeso’s Phase III HARMONi-2 trial in China showed a statistically significant overall survival benefit for ivonescimab monotherapy versus pembrolizumab in PD-L1–positive advanced NSCLC, reinforcing the drug’s clinical profile while it remains investigational in Summit’s territories.

On September 2, 2026, Summit Therapeutics Inc. announced that its partner Akeso Inc. reported a statistically significant overall survival benefit for ivonescimab monotherapy versus pembrolizumab monotherapy in PD-L1–positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) in the randomized, double-blind Phase III HARMONi-2 trial conducted in China. The company noted that these OS results, which follow prior positive progression-free survival data that supported China National Medical Products Administration approval of ivonescimab in 2025, will be presented at an upcoming medical conference. Summit emphasized that ivonescimab (SMT112 in Summit’s territories) remains investigational in its licensed regions, outlined its broader global Phase III development program across NSCLC and other solid tumors, and reminded investors of its pending U.S. Biologics License Application for ivonescimab based on the separate HARMONi study, with an FDA PDUFA date of November 14, 2026.

Filing Facts

CIK

1599298

Ticker

SMMT

Form

8K

Source Type

fda

Accession

0001599298-26-000076

Alert Tier

6